Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Novartis AG ADR (NVSN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,540.01 0.00    0.00%
12/04 - Delayed Data. Currency in MXN ( Disclaimer )
Type:  Equity
Market:  Mexico
ISIN:  US66987V1098 
S/N:  66987V109
  • Volume: 0
  • Bid/Ask: 1,540.00 / 1,658.00
  • Day's Range: 1,540.00 - 1,540.01
Novartis ADR 1,540.01 0.00 0.00%

NVSN Balance Sheet

 
Featured here, the Balance Sheet for Novartis AG ADR, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2024
31/03
2023
31/12
2023
30/09
2023
30/06
Total Current Assets - 30481 45660 33493
Cash and Short Term Investments - 14073 12816 11072
Cash - - - -
Cash & Equivalents - 13393 12405 10885
Short Term Investments - 680 411 187
Total Receivables, Net - 9247 7099 9543
Accounts Receivables - Trade, Net - 7107 6819 9195
Total Inventory - 5913 5610 8228
Prepaid Expenses - 764 - -
Other Current Assets, Total - 484 20135 4650
Total Assets - 99945 112697 110979
Property/Plant/Equipment, Total - Net 10542 10924 10344 12277
Property/Plant/Equipment, Total - Gross - 22803 - -
Accumulated Depreciation, Total - -11879 - -
Goodwill, Net - 23341 23416 29522
Intangibles, Net - 26879 26418 28003
Long Term Investments - 1827 1530 1758
Note Receivable - Long Term - 2140 280 348
Other Long Term Assets, Total 1689 1966 1701 1883
Other Assets, Total 4695 2357 22685 7565
Total Current Liabilities - 26390 48393 31909
Accounts Payable - 4926 3870 5350
Payable/Accrued - - - -
Accrued Expenses - 5174 - -
Notes Payable/Short Term Debt - 3893 - -
Current Port. of LT Debt/Capital Leases 8564 2512 5668 8536
Other Current liabilities, Total 16662 9885 38855 18023
Total Liabilities - 53195 74452 59048
Total Long Term Debt 18720 20034 19521 19804
Long Term Debt 17191 18436 18068 18259
Capital Lease Obligations - 1598 1453 1545
Deferred Income Tax - 2248 2457 2526
Minority Interest - 83 81 84
Other Liabilities, Total 4178 -119 2993 3718
Total Equity - 46750 38245 51931
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total - 825 825 842
Additional Paid-In Capital - - - -
Retained Earnings (Accumulated Deficit) - 49649 42333 55682
Treasury Stock - Common -17 -41 -32 -52
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -4854 -3683 -4881 -4541
Total Liabilities & Shareholders' Equity 94334 99945 112697 110979
Total Common Shares Outstanding 2040.41 2044.03 2055.46 2068.26
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVS Comments

Write your thoughts about Novartis N
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email